“Three male narco-terrorists were killed during this action,” the post said.

Revolution Medicines has commenced the shipment of its experimental pancreatic cancer drug, a significant step for patients battling this aggressive disease. The company’s CEO, Mark Goldsmith, announced the launch of shipments during a recent STAT event, emphasizing the urgency and demand for this treatment.

Patients have been eagerly awaiting access to the drug since mid-April, when Revolution reported promising results from a Phase 3 clinical trial that demonstrated the drug's potential to extend life.

This early access program, authorized by the Food and Drug Administration, allows physicians to provide the drug to patients who may benefit from it before full regulatory approval is granted. The Phase 3 trial results were characterized as striking, highlighting the drug's potential impact on a patient population that has few effective treatment options.

As the company begins distribution, it underscores the critical need for innovative therapies in the fight against pancreatic cancer, a condition known for its poor prognosis and limited treatment alternatives.

The early access initiative reflects a growing trend in the pharmaceutical industry to expedite patient access to promising therapies, particularly for diseases with high unmet medical needs.